Trial document
This study has been imported from ClinicalTrials.gov without additional data checks.
DRKS00006386
Trial Description
Title
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Trial Acronym
CREDENCE
URL of the Trial
[---]*
Brief Summary in Lay Language
The goal of this study is to assess whether canagliflozin has a renal and vascular
protective effect in reducing the progression of renal impairment relative to placebo in
participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD)
and macroalbuminuria, who are receiving standard of care including a maximum tolerated
labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
receptor blocker (ARB).
Brief Summary in Scientific Language
This is a randomized (the study medication is assigned by chance), double-blind (neither
physician nor participant knows the identity of the assigned treatment), placebo-controlled
(an inactive substance that is compared with a medication to test whether the medication has
a real effect), parallel-group, multicenter study of the effects of canagliflozin on renal
and cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and
diabetic nephropathy, who are receiving standard of care including a maximum tolerated daily
dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker
(ARB).
The study will consist of a pretreatment phase (several weeks), and a double-blind treatment
phase (up to 66 months). During the pretreatment phase all participants will also receive
diet/exercise counseling for lipid and blood pressure management as well as counseling on
renal and cardiovascular (CV) risk factor medication. A post-treatment follow-up contact or
visit will take place approximately 30 days after the last dose of study drug or the
completion of the study. The total duration of the study is estimated to be about 5.5 years.
Approximately 3,700 participants will be randomized in a 1:1 ratio to canagliflozin or
matching placebo. Participants randomized to canagliflozin will receive a dose of 100 mg
once daily. The overall safety and tolerability of canagliflozin will be evaluated by
collecting information on adverse events, laboratory tests, vital signs (pulse, blood
pressure), physical examination, and body weight.
Organizational Data
- DRKS00006386
- 2014/11/17
- 2014/02/17
- no
- [---]*
- [---]*
Secondary IDs
- 2013-004494-28
- NCT02065791 (ClinicalTrials.gov)
- CR103517 (Janssen Research & Development, LLC)
- 2013-004494-28
- 28431754DNE3001
Health Condition or Problem studied
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- E11.2 - Non-insulin-dependent diabetes mellitus; With renal complications
- N08.3 - Glomerular disorders in diabetes mellitus
Interventions/Observational Groups
- Drug: Canagliflozin
- Drug: Placebo
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Blinded
- patient/subject, investigator/therapist
- Placebo
- Treatment
- Parallel
- III
- [---]*
Primary Outcome
- Time to the first occurrence of an event in the primary composite endpoint; time frame: Baseline, up to Month 66; The primary composite endpoint of the study includes end-stage kidney disease (ESKD), doubling of serum creatinine, renal or cardiovascular (CV) death.
Secondary Outcome
- Time to the first occurrence of an event in the CV composite endpoint; time frame: Baseline, up to Month 66; The CV composite endpoint includes CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalized congestive heart failure and hospitalized unstable angina.
- Time to the first occurrence of an event in the renal composite endpoint; time frame: Baseline, up to Month 66; The renal composite endpoint includes ESKD, doubling of serum creatinine, and renal death.
- Time to all-cause death; time frame: Baseline, up to Month 66; All deaths occurring during the study from any cause.
Countries of Recruitment
- United States
- Argentina
- Australia
- Bulgaria
- Canada
- Czech Republic
- Germany
- Hong Kong
- Hungary
- Korea, Republic of
- Malaysia
- Mexico
- New Zealand
- Philippines
- Poland
- Romania
- Russian Federation
- South Africa
- Spain
- Ukraine
- United Kingdom
Locations of Recruitment
Recruitment
- [---]*
- 2014/02/27
- 3700
- Multicenter trial
- International
Inclusion Criteria
- Both, male and female
- 30 Years
- no maximum age
Additional Inclusion Criteria
- Type 2 diabetes mellitus with an HbA1c >= 6.5% and <=10.5%, with an estimated
glomerular filtration rate (eGFR) of >= 30 and < 90 mL/min/1.73m2
- Participants need to be on a maximum tolerated labeled daily dose of an
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
for at least 4 weeks prior to randomization
- Must have a urine albumin to creatinine ratio (UACR) of > 300 mg/g and <= 5000 mg/g
Exclusion Criteria
- History of diabetic ketoacidosis or type 1 diabetes mellitus
- History of hereditary glucose-galactose malabsorption or primary renal glucosuria
- Renal disease that required treatment with immunosuppressive therapy
- Known significant liver disease
- Current or history of New York Heart Association (NYHA) Class IV heart failure
Addresses
-
start of 1:1-Block address primary-sponsor
- Janssen Research & Development, LLC
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address other
- The George Institute for Global Health, Australia
end of 1:1-Block address otherstart of 1:1-Block address contact other- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address scientific-contact
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC Clinical Trial
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- [---]*
- [---]*
- JNJ.CT at sylogent.com
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- 2
- 2014/12/02